{"id":88989,"date":"2026-01-21T20:24:16","date_gmt":"2026-01-21T20:24:16","guid":{"rendered":"https:\/\/www.europesays.com\/lt\/88989\/"},"modified":"2026-01-21T20:24:16","modified_gmt":"2026-01-21T20:24:16","slug":"nauseda-pakviete-biofarmacijos-kompanija-astrazeneca-plestis-lietuvoje-respublika-lt","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/lt\/88989\/","title":{"rendered":"Naus\u0117da pakviet\u0117 biofarmacijos kompanij\u0105 \u201eAstraZeneca\u201c pl\u0117stis Lietuvoje – Respublika.lt"},"content":{"rendered":"

\u00d7<\/p>\n

(1\/1) \u201eAstraZeneca\u201c vakcinos. Asociatyvi EPA-Eltos nuotr. Atsisi\u0173sti<\/a><\/p>\n

\"nuotr.\" 1 nuotr.<\/p>\n

\u201eAstraZeneca\u201c vakcinos. Asociatyvi EPA-Eltos nuotr.<\/p>\n

Pasaulio ekonomikos forume Davose dalyvaujantis valstyb\u0117s vadovas Gitanas Naus\u0117da pasi\u016bl\u0117 pasaulinei biofarmacijos kompanijai \u201eAstraZeneca\u201c apsvarstyti pl\u0117tr\u0105 Lietuvoje, pabr\u0117\u017edamas, kad \u0161alyje sukurtos palankios s\u0105lygos biotechnologij\u0173 ir farmacijos projektams.<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Susitikime su \u201eAstraZeneca\u201c valdybos pirmininku Micheliu Demare prezidentas pristat\u0117 Lietuvos ekosistemos galimybes.<\/p>\n

Pasak G. Naus\u0117dos, Lietuva turi i\u0161skirtin\u0119 patirt\u012f\u00a0gen\u0173 in\u017einerijos, klinikini\u0173 tyrim\u0173, ret\u0173 lig\u0173 gydymo srityse bei yra reik\u0161mingai suma\u017einusi administracin\u0119 na\u0161t\u0105 inovatyvios gamybos projekt\u0173 pl\u0117trai.<\/p>\n

\u201eEuropai galime pasi\u016blyti medicinos priemoni\u0173 tiekimo grandin\u0117s u\u017etikrinim\u0105 vietoje, investuotojams \u2013 valstyb\u0117s paskatas ir talenting\u0173 mokslinink\u0173 ir darbuotoj\u0173 prieig\u0105. Kvie\u010diu \u201eAstraZeneca\u201c komand\u0105 pla\u010diau \u012fvertinti Lietuvos ekosistemos privalumus ir pl\u0117toti investicin\u012f bendradarbiavim\u0105\u201c, \u2013 susitikime teig\u0117 prezidentas.<\/p>\n

\u0160alies vadovas taip pat pabr\u0117\u017e\u0117, kad\u00a0gyvyb\u0117s moksl\u0173 industrija Lietuvoje auga grei\u010diau nei likusi ekonomikos dalis ir \u0161iuo metu sudaro jau 2,6 proc. bendrojo vidaus produkto (BVP).<\/p>\n

Planuojama, kad iki 20230 met\u0173 \u0161io sektoriaus dalis pasieks 5 proc. BVP.<\/p>\n

Naujausios \u017einios<\/p>\n

<\/p>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

Patiko straipsnis? Leisk mums apie tai su\u017einoti. Nepamir\u0161k pasidalinti Facebook! <\/p>\n

\"L\"\/<\/p>\n

\"F\"<\/p>\n


\n\tNesutinkate – diskutuokime!

\n\tNepykite komentatoriai, bet komentarai su keiksma\u017eod\u017eiais bus \u0161alinami automati\u0161kai, be atsipra\u0161ymo.\n <\/p>\n


\n Respublika.lt pasilieka teis\u0119 pa\u0161alinti nekult\u016bringus, keiksma\u017eod\u017eiais pagardintus, su tema nesusijusius, kito asmens vardu pasira\u0161ytus, \u012fstatymus pa\u017eeid\u017eian\u010dius, \u0161lam\u0161t\u0105 reklamuojan\u010dius ar nusikalsti kurstan\u010dius komentarus. Jei kurstysite smurt\u0105, rasin\u0119, tautin\u0119, religin\u0119 ar kitokio pob\u016bd\u017eio neapykant\u0105, \u017evirbliu i\u0161skrid\u0119 j\u016bs\u0173 \u017eod\u017eiai gr\u012f\u017edami gali virsti ton\u0105 sverian\u010diu jau\u010diu – specialiosioms Lietuvos tarnyboms pareikalavus suteiksime j\u016bs\u0173 duomenis.\n <\/p>\n","protected":false},"excerpt":{"rendered":"\u00d7 (1\/1) \u201eAstraZeneca\u201c vakcinos. Asociatyvi EPA-Eltos nuotr. Atsisi\u0173sti 1 nuotr. \u201eAstraZeneca\u201c vakcinos. Asociatyvi EPA-Eltos nuotr. Pasaulio ekonomikos forume…\n","protected":false},"author":2,"featured_media":88990,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[25,18493,30,31,18228,34,35,24,32,33,37,39,36,38,40,23,417,22,28,29,26,27,46],"class_list":{"0":"post-88989","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-lietuva","8":"tag-antrastes","9":"tag-astrazeneca","10":"tag-breaking-news","11":"tag-breakingnews","12":"tag-davosas","13":"tag-featured-news","14":"tag-featurednews","15":"tag-headlines","16":"tag-latest-news","17":"tag-latestnews","18":"tag-lietuva","19":"tag-lietuviu","20":"tag-lithuania","21":"tag-lithuanian","22":"tag-lt","23":"tag-naujienos","24":"tag-nauseda","25":"tag-news","26":"tag-populiariausios-naujienos","27":"tag-populiariausiosnaujienos","28":"tag-top-stories","29":"tag-topstories","30":"tag-verslas"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lt\/115934964180019649","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/88989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/comments?post=88989"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/88989\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media\/88990"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media?parent=88989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/categories?post=88989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/tags?post=88989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}